Vaxcyte, Inc. — Director's Dealing 2022

Jul 6, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2022-07-01

Reporting Person: Wassil Jim (Chief Operating Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-07-01	Common Stock	M	2800	$2.42	Acquired	47306	Direct
2022-07-01	Common Stock	S	2800	$22.00	Disposed	44506	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-07-01	Stock Option (right to buy)	$2.42	M	2800	Disposed	2029-12-16	Common Stock (2800)	Direct

Footnotes

F1: Includes 1,562 shares acquired under the Issuer's Employee Stock Purchase Plan on May 17, 2022.

F2: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F3: 1/4 of the shares subject to the option vested on December 1, 2020, and 1/48 of the shares vest monthly thereafter.